Business
Nutriband Unveils Groundbreaking Innovation in Transdermal Medications
Revolutionary AVERSA™ Technology Sets New Standard for Opioid Patch Safety --News Direct--ORLANDO, FL / September 20, 2023 (PlatoData via 500NewsWire) --
About this update from Nutriband Inc.
[{"type":"text","content":"Revolutionary AVERSA™ Technology Sets New Standard for Opioid Patch Safety\n--News Direct--ORLANDO, FL / September 20, 2023 (PlatoData via 500NewsWire) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a leading developer of transdermal pharmaceutical products, proudly announces the issuance of a U.S. patent for its cutting-edge AVERSA™ Technology. This groundbreaking innovation, utilizing taste aversion, marks a paradigm shift in addressing the primary routes of abuse associated with opioid-based transdermal patches.The newly granted patent, numbered U.S. patent 11,759,431, titled \"Abuse and Misuse Deterrent Transdermal Systems,\" significantly bolsters Nutriband's intellectual property protection in the United States. It covers a range of abuse deterrent transdermal products, all rooted in the proprietary AVERSA™ abuse deterrent technology. This pioneering technology seamlessly integrates into transdermal patches, effectively countering abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.Nutriband's flagship product in development, AVERSA™ Fentanyl, leads the charge in revolutionizing pain management. It aims to become the market's premier abuse deterrent pain patch, setting new standards for safety. This patent signifies a pivotal milestone in Nutriband's strategic vision to fortify its intellectual property foundation around its proprietary abuse deterrent technology. With a global reach encompassing 45 countries, Nutriband's IP portfolio solidifies its position in the market. AVERSA™ Fentanyl, the company's flagship product, recently projected peak annual U.S. sales ranging from $80M to $200M.Nutriband's AVERSA™ abuse deterrent transdermal technology presents a transformative solution to enhance the safety profile of transdermal drugs susceptible to abuse. AVERSA™ not only ensures continued access for patients in need but also minimizes the risk of abuse, diversion, misuse, and accidental exposure. Backing this pioneering technology is a robust intellectual property portfolio, with patents granted in various countries, including the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.About Nutriband Inc.Nutriband Inc. is a leader in developing transdermal pharmaceutical products. At the forefront is the company's flagship product, an abuse deterrent fentanyl patch incorporat...